Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease

doi:10.5497/wjp.v5.i1.44

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14242)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

943

WORD

454

HTML

9207

Figures (1-2)

622

Tables (1-1)

265

Sum=11491

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1102

Download

1649

Sum=2751

Mar 9, 2016 (publication date) through Jan 13, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Pharmacol. Mar 9, 2016; 5(1): 44-50
Published online Mar 9, 2016. doi: 10.5497/wjp.v5.i1.44

Full Size Figure Download Figure

Figure 2 Anti-adalimumab antibodies detection. TMB: 3,3’,5,5’-Tetramethylbenzidine.

Citation: Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50
URL: https://www.wjgnet.com/2220-3192/full/v5/i1/44.htm
DOI: https://dx.doi.org/10.5497/wjp.v5.i1.44